27. Clinical and paraclinical characteristics of patients with primary immune thrombocytopenia
Main Article Content
Abstract
This study describes the clinical and paraclinical characteristics of patients with Immune ThrombocytoPenia (ITP) and identifies factors associated with the risk of chronic progression. The study was conducted on 89 ITP patients at Military Hospital 103 from January 2016 to December 2024, including 20 patients with chronic ITP and 69 patients with non-chronic ITP. Patients in the chronic ITP group had a significantly higher median age than those in the non-chronic ITP group (p = 0.001). Significant differences were observed between the two groups in terms of reason for hospitalization, onset of disease, levels of bleeding, and lymphocyte count, with p values of 0.0001, 0.01, 0.0001, and 0.031, respectively. The risk of chronic progression in ITP patients over 60 years old is 6.963 times higher, 4.09 times higher in cases with a gradual onset, and 4.255 times higher when the lymphocyte count is reduced. There is a correlation between age, onset time, and lymphocyte count with the risk of chronic progression in ITP patients.
Article Details
Keywords
Immune ThrombocytoPenia (ITP), Chronic Immune ThrombocytoPenia, Military Hospital 103
References
2. Nguyễn Thị Mộng Hồng, Nguyễn Thị Mai Anh, Bùi Quang Vinh và cộng sự. Các yếu tố liên quan đến bệnh giảm tiểu cầu miễn dịch mạn tính ở trẻ em tại Bệnh viện Nhi Đồng 1. Tạp chí Y học Việt Nam. 2023; 525(1B): 197-202.
3. Kuter DJ, Newland A, Chong BH, et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. British Journal of Haematology. 2019; 185(3): 503-513.
4. Sun Y, Long S, Liu W. Risk factors and psychological analysis of chronic immune thrombocytopenia in children. International Journal of General Medicine. 2020: 1675-1683.
5. ElAlfy M, Farid S, Maksoud AA. Predictors of chronic idiopathic thrombocytopenic purpura. Pediatric Blood & Cancer. 2010; 54(7): 959-962.
6. Bộ y tế. Hướng dẫn chẩn đoán và điều trị một số bệnh lý huyết học. 2022; 59-70.
7. González-López TJ, Fernández-Fuertes F, Hernández-Rivas JA, et al. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. International journal of hematology. 2017; 106: 508-516.
8. Snell Taylor SJ, Nielson CM, Breskin A, et al. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic immune thrombocytopenia in European clinical practice. Advances in Therapy. 2021; 38: 2673-2688.
9. Wang Y, Huang Y. Clinical value of megakaryocytes in the diagnosis and treatment of children with immune thrombocytopenic purpura. Chinese Journal of Primary Medicine and Pharmacy. 2019: 2830-2834.
10. Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). Journal of clinical medicine. 2017; 6(2): 16.
11. Vianello F, Cannella L, Coe D, et al. Enhanced and aberrant T cell trafficking following total body irradiation: a gateway to graft-versus-host disease? British journal of haematology. 2013; 162(6): 808-818.
12. Virk ZM, Leaf RK, Kuter DJ, et al. Avatrombopag for adults with early versus chronic immune thrombocytopenia. American Journal of Hematology. 2024; 99(2): 155-162.
13. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. New England Journal of Medicine. 2002; 346(13): 995-1008.
14. Ahmed I, Rajpurkar M, Thomas R, et al. Initial lymphocyte count and the development of persistent/chronic immune thrombocytopenic purpura. Pediatric Blood & Cancer. 2010; 55(3): 508-511.
15. Doobaree IU, Newland A, McDonald V, et al. Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry. European Journal of Haematology. 2019; 102(5): 416-423.